83701

Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoretic, nuclear magnetic resonance, ultracentrifugation)

CPT code 83701 involves the high-resolution fractionation and quantitation of blood lipoproteins, which may include lipoprotein subclasses using methods such as electrophoresis, nuclear magnetic resonance (NMR) spectroscopy, or ultracentrifugation. Traditional lipid panels measure total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. However, patients with similar traditional lipid profiles can have vastly different risks for cardiovascular disease due to the heterogeneity of lipoprotein particles. This test measures the size, density, and number of various lipoprotein particles, such as small dense LDL particles and large buoyant HDL particles. By quantifying these specific subclasses, healthcare providers can better stratify cardiovascular risk, especially in patients with metabolic syndrome, diabetes mellitus, or those with intermediate risk based on standard lipid testing. The procedure involves obtaining a blood sample, usually serum or plasma, which is then subjected to advanced laboratory techniques. Nuclear magnetic resonance (NMR) measures the magnetic resonance signal emitted by lipid methyl groups, which varies based on particle size. Gel electrophoresis separates particles based on their size and electrical charge, while ultracentrifugation separates lipoproteins based on their buoyant density. The laboratory scientist analyzes the results, and a comprehensive report is generated detailing particle numbers and subclass distribution. Providers use this exhaustive clinical intelligence to tailor lipid-lowering therapies, such as statins, fibrates, or PCSK9 inhibitors, and recommend specific lifestyle modifications. Advanced lipoprotein testing represented by code 83701 serves a critical role in preventive cardiology and endocrinology. Standard lipid profiles often fail to identify the atherogenic risk associated with particle concentration, particularly in patients presenting with normolipidemia who nonetheless suffer acute coronary events. The atherogenic lipoprotein phenotype, characterized by an increased number of small, dense LDL particles, elevated triglycerides, and decreased HDL cholesterol, is strongly associated with insulin resistance. High-resolution fractionation allows for the precise measurement of these small, dense LDL particles that easily penetrate the arterial endothelium, undergo oxidation, and promote foam cell formation, leading to atherosclerosis. Additionally, this testing evaluates HDL subclasses; while total HDL-C might be normal, the patient may lack the large, mature, cardioprotective HDL particles required for efficient reverse cholesterol transport. Consequently, 83701 represents a sophisticated diagnostic tool that shifts the paradigm from simple cholesterol mass measurement to a more nuanced particle-driven assessment of atherosclerotic cardiovascular disease (ASCVD) risk. The comprehensive nature of this assay necessitates rigorous quality control and specialized laboratory equipment, reflecting its immense value in modern personalized medicine and targeted therapeutic intervention.

Clinical Indications

  • Cardiovascular risk stratification in patients with intermediate risk on standard lipid panels.
  • Evaluation of patients with a strong family history of premature coronary artery disease (CAD).
  • Management and assessment of patients with metabolic syndrome or type 2 diabetes mellitus.
  • Assessment of residual risk in patients already on statin therapy but not achieving expected cardiovascular risk reduction.
  • Identification and quantification of small, dense LDL particles in suspected atherogenic dyslipidemia.
  • Evaluating complex hyperlipidemia that is unresponsive to standard therapeutic dietary and pharmacologic interventions.

Procedure Steps

  1. Instruct the patient to fast for 9 to 12 hours prior to the blood draw to ensure accurate baseline lipid and lipoprotein measurements.
  2. Perform standard phlebotomy to collect a venous blood sample into an appropriate collection tube, such as a serum separator tube or EDTA plasma tube.
  3. Centrifuge the blood sample within the required time frame to separate the serum or plasma from the cellular blood components.
  4. Transport the biological specimen to a specialized clinical laboratory while maintaining strict temperature controls, typically refrigerated.
  5. Prepare the sample for the specific high-resolution analytical method ordered, such as NMR spectroscopy, polyacrylamide gel electrophoresis, or analytical ultracentrifugation.
  6. Execute the fractionation process to separate the total lipoprotein pool into discrete subclasses based on physical properties like size, density, or surface charge.
  7. Quantify the exact particle numbers and sizes for specific low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL) subclasses.
  8. Perform data analysis to generate a comprehensive diagnostic report detailing particle concentrations and corresponding cardiovascular risk stratification metrics.
  9. Deliver the final pathology report to the ordering provider for clinical correlation and therapeutic decision-making.

Coding Guidelines

  • Do not report CPT 83701 in conjunction with 83721 (Lipoprotein, direct measurement; LDL cholesterol) unless distinct medical necessity is thoroughly documented and appropriately modified.
  • Ensure the patient's medical record specifically supports the medical necessity for advanced lipoprotein testing over standard lipid panels (e.g., CPT 80061).
  • Review payer-specific Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs), as many payers restrict NMR lipid profiles to specific high-risk ICD-10 diagnoses or consider them investigational for general screening.
  • Code 83701 encompasses the measurement of all evaluated subclasses; do not bill separate codes for the individual subclasses of lipoproteins.
  • If a standard lipid panel (80061) is performed on the same date of service, verify bundling rules; an appropriate modifier (such as 59 or XU) may be required if the tests are clinically distinct, though simultaneous billing often faces payer scrutiny.

Associated ICD-10 Codes